We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · September 06, 2021

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy

JAMA ophthalmology

 

Additional Info

JAMA ophthalmology
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
JAMA Ophthalmol 2021 Aug 05;[EPub Ahead of Print], DM Brown, CC Wykoff, D Boyer, JS Heier, WL Clark, A Emanuelli, PM Higgins, M Singer, DM Weinreich, GD Yancopoulos, AJ Berliner, K Chu, K Reed, Y Cheng, R Vitti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading